<DOC>
	<DOC>NCT00566020</DOC>
	<brief_summary>This study is planned to assess the long-term safety of lamotrigine in Japanese patients with bipolar I disorder who will continue into the 52-week extension upon completion of a double-blind comparative study (Study No.: SCA104779 (NCT00550407)), i.e. the patients who receive the addition of any additional treatment to intervene in a mood episode in the double-blind phase or the patients completing the double-blind phase.</brief_summary>
	<brief_title>A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Of subjects participating in the preceding doubleblind study, those who are judged by the investigator/subinvestigator to have well tolerated the doubleblind treatment and to be eligible for the 52week extension treatment Sex: either sex. Female of childbearing potential will be eligible for inclusion in this study. However they have to have a negative pregnancy test at the start of this study, agree to further pregnancy testing at the time points determined in study assessments and procedures and practice one of the following methods of contraception from the start of this study until the end of the followup examination: Abstinence Oral contraceptive, either combined or progestogen alone (except during the Dosage Adjustment Phase) Injectable progestogen Implants of levonorgestrel Estrogenic vaginal ring (except during the Dosage Adjustment Phase) Percutaneous contraceptive patches (except during the Dosage Adjustment Phase) Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject Double barrier method: condom or occlusive cap (diaphragm or cervical / vault caps) plus spermicidal agent (foam / gel / film / cream / suppository) In/Out patient: Either Informed consent: the subject capable of giving written informed consent Has a score of 3 or more on item of the HAMD related to suicide or is at a high suicidal risk in the judgment of the investigator/subinvestigator Has a history of severe rash or rash due to antiepileptic drugs Patients with severe hepatic/renal/cardiac/pulmonary disorder or hematopoietic disorder. The severity refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences" (PAB/SD Notification No. 80, dated 29 June 1992) Patients have less than 5 years of remission history from clinically significant malignancy (other than e.g. basal cell or squamous cell skin cancer, insitu carcinoma of cervix or prostate CA in situ) Patients with chronic hepatitis typeB and /or typeC which is positive of hepatitis B surface antigen （HBsAg）and/or hepatitis C antibody Has an acute or chronic illness likely to impair drug absorption, distribution, metabolism or excretion or has any unstable physical symptoms likely to require hospitalisation during participation in the study Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study Has a history or current diagnosis of epilepsy Has received an investigational drug within 30 days of screening Patients with a history of drug allergy to any ingredient of the testdrug Patients whom the investigator or subinvestigator considers ineligible for the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Open-label extension</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Lamotrigine</keyword>
	<keyword>Safety</keyword>
	<keyword>Bipolar I disorder</keyword>
</DOC>